

**IN THE CLAIMS:**

1-4. (Cancelled)

5. (Previously Presented) A composition comprising a cyclodextrin-containing polymer and a therapeutic agent and a complexing agent comprising at least one functional group and at least one host/guest moiety that forms an inclusion complex with a host/guest moiety of said polymer, wherein the polymer, the therapeutic agent, and the complexing agent are separate molecules.


6. (Previously Presented) A composition of claim 5, wherein said therapeutic agent is selected from an antibiotic, a steroid, a polynucleotide, small molecule pharmaceutical, a virus, a plasmid, a peptide, a peptide fragment, a chelating agent, a biologically active macromolecule, and mixtures thereof.

7. (Original) A composition of claim 6, wherein said therapeutic agent is a polynucleotide.

8-10. (Cancelled)


11. (Previously Presented) A composition of claim 5, wherein the host/guest of the complexing agent is selected from adamantyl, naphthyl, cholesterol, cyclodextrin, and mixtures thereof.

12. (Previously Presented) A composition of claim 5, wherein the complexing agent is a compound of the formula:



wherein

J is  $-\text{NH}-$ ,  $-\text{C}(=\text{O})\text{NH}-\text{CH}_2\text{d}-$ ,  $-\text{NH}-\text{C}(=\text{O})-(\text{CH}_2)_d-$ ,  $-\text{CH}_2\text{SS}-$ ,  $-\text{C}(=\text{O})\text{O}-(\text{CH}_2)_e\text{O}-\text{P}(=\text{O})(\text{O}-$



Y is an additional host-guest functionality;

R<sup>1</sup> is  $-(\text{CH}_2)\text{-CO}_2\text{H}$ , an ester or salt thereof; or  $-(\text{CH}_2)_a\text{-CONH}_2$ ;

PEG is  $-\text{O}(\text{CH}_2\text{CH}_2\text{O})_z-$ , where z varies from 2 to 500;

L is H,  $-\text{NH}$ ,  $-\text{NH}-(\text{C=O})-(\text{CH}_2)_e-(\text{C=O})\text{-CH}_2-$ ,  $-\text{S}(\text{=O})_2\text{-HC=CH-}$ ,  $-\text{SS-}$ ,  $-\text{C}(=\text{O})\text{O-}$ , or a carbohydrate residue;

a is 0 or 1;

b is 0 or 1;

d ranges from 0 to 6;

e ranges from 1 to 6;

n ranges from 0 to 6;


q ranges from 1 to 5;

w ranges from 1 to 5;

y is 1; and


x is 0 or 1.

13. (Previously Presented) A composition of claim 5, wherein the complexing agent is a compound of the formula:



wherein

J is  $-\text{NH}-$ ,  $-\text{C}(=\text{O})\text{NH}-\text{CH}_2-$ <sub>d</sub>,  $-\text{NH}-\text{C}(=\text{O})-(\text{CH}_2)$ <sub>d</sub> $-\text{}$ ,  $-\text{CH}_2\text{SS}-$ ,  $-\text{C}(=\text{O})\text{O}-(\text{CH}_2)$ <sub>e</sub> $-\text{O}-\text{P}(=\text{O})(\text{O}-$



**Y** is an additional host-guest functionality;

$R^1$  is  $-(CH_2)_n-CO_2H$ , an ester or salt thereof; or  $-(CH_2)_n-CONH_2$ ;

PEG is  $-\text{O}(\text{CH}_2\text{CH}_2\text{O})_z-$ , where z varies from 2 to 500;

L is H, -NH, -NH-(C=O)-(CH<sub>2</sub>)<sub>e</sub>-(C=O)-CH<sub>2</sub>-; -S(=O)<sub>2</sub>-HC=CH-; -SS-, -C(=O)O-, or a carbohydrate residue;

a is 0 or 1;

b is 0 or 1;

d ranges from 0 to 6;

e ranges from 1 to 6;

n ranges from 0 to 6;

y is 1; and

$x$  is 0 or 1.

14. (Previously Presented) A composition of claim 5, wherein the at least one functional group includes a group selected from a ligand, a nuclear localization signal, an endosomal release peptide, an endosomal release polymer, or a membrane permeabilization agent.

15. (Previously Presented) A composition of claim 5, wherein the at least one functional group includes a moiety that increases the solubility of the composition under biological conditions relative to a composition of the polymer and therapeutic agent alone.
16. (Previously Presented) A composition of claim 5, wherein the at least one functional group includes a moiety that stabilizes the composition under biological conditions relative to a composition of the polymer and therapeutic agent alone.
17. (Previously Presented) A composition of claim 5, wherein the at least one functional group includes a therapeutic agent reversibly bound to the complexing agent.
18. (Previously Presented) A composition of claim 5, wherein the complexing agent further comprises a spacer group.
19. (Cancelled)
20. (Previously Presented) A composition of claim 5, wherein the polymer comprises a guest moiety that forms an inclusion complex with a host moiety of the complexing agent.
21. (Previously Presented) A composition of claim 20, wherein the guest moiety is an adamantyl group and the host moiety is a cyclodextrin moiety.